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RESEARCH REPORT

Vincristine and bortezomib cause axon outgrowth
and behavioral defects in larval zebrafish
Tahsin M. Khan1 , Nathan Benaich1 , Clare F. Malone1 , Rebecca L. Bernardos2 ,
Amy R. Russell1 , Gerald B. Downes3 , Michael J. Barresi2 , and Lara D. Hutson1,4
1

Department of Biology, Williams College, Williamstown, MA, USA; 2 Department of Biology, Smith College, Northampton,
MA, USA; 3 Department of Biology, University of Massachusetts, Amherst, MA, USA; and 4 Program in Neuroscience,
Williams College, Williamstown, MA, USA

Abstract Peripheral neuropathy is a common side effect of a number of pharmaceutical
compounds, including several chemotherapy drugs. Among these are vincristine sulfate,
a mitotic inhibitor used to treat a variety of leukemias, lymphomas, and other cancers,
and bortezomib, a 26S proteasome inhibitor used primarily to treat relapsed multiple
myeloma and mantle cell lymphoma. To gain insight into the mechanisms by which these
compounds act, we tested their effects in zebrafish. Vincristine or bortezomib given during
late embryonic development caused significant defects at both behavioral and cellular
levels. Intriguingly, the effects of the two drugs appear to be distinct. Vincristine causes
uncoordinated swimming behavior, which is coupled with a reduction in the density
of sensory innervation and overall size of motor axon arbors. Bortezomib, in contrast,
increases the duration and amplitude of muscle contractions associated with escape
swimming, which is coupled with a preferential reduction in fine processes and branches
of sensory and motor axons. These results demonstrate that zebrafish is a convenient
in vivo assay system for screening potential pharmaceutical compounds for neurotoxic
side effects, and they provide an important step toward understanding how vincristine and
bortezomib cause peripheral neuropathy.
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and Thomas, 2005). Peripheral neuropathy can be
caused by a number of pharmaceutical compounds,
including many with chemotherapeutic applications
(Hilkens and ven den Bent, 1997; Windebank and
Grisold, 2008).
Although far from being the only chemotherapy
drugs to cause peripheral neuropathy, microtubule
disruptors and proteasome inhibitors are of particular interest due to their high rates of neuropathic
side effects. Vincristine sulfate is a microtubule polymerization inhibitor used to treat various leukemias,
Hodgkin’s and non-Hodgkin’s lymphomas, and a
number of other cancers (McLeod and Penny, 1969;

Introduction
Peripheral neuropathies, characterized by degeneration or dysfunction of peripheral nerves, are
collectively one of the most frequently reported neurological disorders (MacDonald et al., 2000). Causes of
peripheral neuropathy are many and include genetics,
disease, trauma, and toxic chemical exposure (Dyck
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Kempin et al., 1982). A naturally occurring compound
of the Vinca alkaloid class, vincristine, disrupts mitotic
spindle formation by binding α/β tubulin heterodimers,
thereby competitively inhibiting their incorporation into
growing microtubules (Himes et al., 1976; Haskins
et al., 1981; Gigant et al., 2005). Vincristine causes
a high incidence of dose-dependent peripheral neuropathy in human patients (Rosenthal and Kaufman,
1974; Legha, 1986). This is likely due to the disruption
of axonal microtubule networks and the impairment
of transport along these scaffolds, ultimately leading to axonal degeneration (Topp et al., 2000; Silva
et al., 2006).
Bortezomib is used primarily to treat relapsed and
refractory multiple myeloma (Montagut et al., 2005;
San Miguel et al., 2006) and mantle cell lymphoma
(Leonard et al., 2006; Kane et al., 2007). Peripheral
neuropathy is the primary dose-limiting side effect of
bortezomib, and like vincristine, this side effect occurs
in a large fraction of patients (Cavaletti and NobileOrazio, 2007; Chaudhry et al., 2008; Delforge et al.,
2010). The mechanism by which bortezomib induces
peripheral neuropathy is unknown, but it may be due
to dysregulation of calcium homeostasis, neurotrophin
function, or both (Argyriou et al., 2008).
Despite their neurotoxicity, vincristine and bortezomib are important therapies. It is therefore critical
to understand the mechanisms by which these compounds cause peripheral neuropathy in vivo with the
goal of discovering ways in which these debilitating
side effects can be prevented (Cavaletti and NobileOrazio, 2007). Zebrafish have long been a favored
model system to study vertebrate development due to
their small size, rapid development, ease of handling,
embryonic transparency, amenability to genetic manipulation, and low maintenance costs. Increasingly, the
zebrafish system has been used to study the biology
of cancer (Stoletov and Klemke, 2008; Frazer et al.,
2009; Smith et al., 2010) and other diseases (Berman
et al., 2003; Taylor et al., 2004; Hsu et al., 2007; Kari
et al., 2007). Because zebrafish embryos and larvae
are permeable to many small molecules when added
to normal growth medium (Khersonsky et al., 2003;
Peterson et al., 2004; Murphey et al., 2006; Choi et al.,
2007), they can be used to rapidly assay the effects of
potential chemotherapy drugs (Mizgirev and Revskoy,
2010). We have taken advantage of these features of
the zebrafish system to investigate the cellular and
behavioral effects of vincristine and bortezomib during
late embryonic development. Our findings demonstrate that both vincristine and bortezomib cause
sensorimotor defects and that these defects are correlated with underlying changes in sensory and motor
axon outgrowth and/or maintenance. The cellular and
behavioral effects of these drugs appear to be distinct,

consistent with the fact that these drugs have different
cellular targets.

Materials and Methods
Fish care
Zebrafish were bred and maintained using
standard procedures and in accordance with Williams
College animal and welfare assurance certificate
A3133-01. AB* wild-type or HB9::EGFP (FlanaganSteet et al., 2005) fish were used for all studies.
AB* were obtained from the Zebrafish International
Resource Center (Eugene, OR, USA), and HB9::EGFP
were obtained from the laboratory of Dr. Joshua Sanes
at Harvard University. Embryos were raised in E3
medium (5 mM NaCl, 0.17 mM KCl, 0.33 mM CaCl2 ,
0.33 mM MgSO4 ) containing 0.00016% methylene
blue and staged as equivalent hours post-fertilization
(hpf) at 28.5◦ C (Kimmel et al., 1995).

Drug application
Vincristine sulfate was obtained from MP
Biomedicals (Solon, OH, USA), and bortezomib was
obtained from Chemietek (Indianapolis, IN, USA). We
chose to test vincristine concentrations between 25
and 100 μM based on studies in Xenopus laevis
(Ubbels et al., 1983; Ton and Parng, 2005) and
bortezomib between 10 and 50 μM based on its
relative effective dose in cell culture (Montagut et al.,
2005). Vincristine was dissolved in sterile, distilled
water to 25 mM. This stock solution and dimethyl
sulfoxide (DMSO) were diluted directly into E3 medium
containing 1% DMSO. DMSO has been shown to be
a safe carrier solvent in zebrafish embryos at up to
1.5% (Hallare et al., 2006), and 1% DMSO does not
have any effect on cell cycle progression or motor axon
outgrowth in our hands. Bortezomib was dissolved in
85% DMSO in water to a concentration of 4.16 mM.
This stock was diluted directly into E3 containing
1% DMSO. Manually dechorionated 24 hpf embryos
were transferred into Petri dishes containing each
solution and placed at 28.5◦ C for 24 h. All experiments
were performed on age-matched siblings. Larvae were
washed three times in E3 prior to analysis.

Behavioral analysis
Each drug was washed out as described above.
Ten larvae each were tested for a response to five
stimuli each to the head and to the tail using a probe. To
preclude any pre-stimulus modulation of the response
(Burgess and Granato, 2007), we waited a minimum
of 5 s between each stimulus.
Except in the case of 50 μM bortezomib (where
only two larvae mounted an escape response), the
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escape responses of a minimum of five 50 hpf larvae
from each sample were recorded. A touch stimulus
was applied to the trunk using a dulled 0.2 mm
insect pin attached to a surgical blade holder, and
responses recorded using a high-speed digital camera
(Fastec Imaging, San Diego, CA, USA) mounted to a
35 mm lens (Nikon, Melville, NY, USA) collecting at
a rate of 500 frames per second (fps). Body bend
angle, or the angle of deviation of the tail, was
measured with the assistance of specialized software
(McKeown et al., 2012), recorded for each frame, and
plotted using MICROSOFT EXCEL. These data were used
to determine body bend amplitude, frequency, and
contraction velocity. Statistical tests were performed
using GRAPHPAD software.

images were segmented, and number of particles was
determined automatically using AUTOQUANT software
(Media Cybernetics, Bethesda, MD, USA). Means
were derived from a minimum of three samples
per concentration. Sensory neuron processes were
quantified in IMAGE J using a previously published
method (Grider et al., 2006). Briefly, 8-bit images
were converted into binary images to calculate
pixel density. Total pixel number for each image
was recorded and used for statistical analysis. For
axon arbor surface areas, individual axonal arbors
were manually isolated and cropped. Images were
then segmented, and AUTOQUANT software was
used to automatically determine the total surface
area of staining. Means were derived from a
minimum of three arbors from a minimum of three
different samples. Fisher’s exact tests were performed
using GRAPHPAD software. ANOVA, Mann-Whitney
U -tests, and Fisher’s exact tests were carried out
using the calculators at http://faculty.vassar.edu/lowry/
VassarStats.html.

Immunohistochemistry
Forty-eight hours post-fertilization larvae were
anesthetized in 0.016% tricaine and fixed in fresh
4% formaldehyde (Ted Pella, Redding, CA, USA) in
phosphate buffered saline (PBS) for 2 h at room
temperature. After fixation, larvae were incubated
for 1–2 h in distilled water, dehydrated through a
methanol series, and stored at −20◦ C in 100%
methanol. Larvae were then either transferred to
acetone for 10 min at −20◦ C and rehydrated through
methanols, or directly rehydrated through a methanol
series and treated with 0.1% collagenase in PBS for
45 min at room temperature. Larvae were incubated
overnight at 4◦ C in one or more of the following
primary antibodies: anti-phospho-histone H3 (Ser10)
(H3P; Millipore, Billerica, MA, USA; 1:100), znp-1
(Developmental Studies Hybridoma Bank, Iowa City,
IA, USA; 1:100), anti-acetylated tubulin (AT; Sigma,
St. Louis, MO, USA; 1:800), or F59 (Developmental
Studies Hybridoma Bank; 1:100). After washing, larvae
were incubated overnight at 4◦ C in one or more
of the following secondary antibodies: Alexa 633
goat-anti-rabbit for H3P (Invitrogen, Grand Island,
NY, USA; 1:200), horseradish peroxidase (HRP)conjugated goat-anti-mouse for znp-1 (Invitrogen;
1:200), and Alexa 488 goat-anti-mouse for AT and
F59 (Invitrogen; 1:200). After washing, HRP was
visualized using the Alexa 546 Tyramide Signal
Amplification kit (Invitrogen). Stained larvae were then
transferred to glycerol and mounted using Vectashield
(Vector Labs, Burlingame, CA, USA).

Results
Vincristine and bortezomib cause an increase
in M-phase cells
To establish that vincristine and bortezomib suppress cellular proliferation in zebrafish larvae, we
stained for phosphorylated (ser10) histone H3 (H3P),
suggestive of M-phase arrest (Murphey et al., 2006).
Vincristine caused a statistically significant dosedependent increase in the number of H3P-positive cells
(Figs. 1A–D and 1E) (p < 0.0001, one-way ANOVA).
These effects were statistically significant at all doses
(Figs. 1A –C ). No increase in mortality was observed
with any dose of vincristine, although larvae treated
with 100 μM vincristine began to exhibit morphological
defects, primarily ventral curvature of the trunk and tail
(Fig. 1D ).
Bortezomib caused a small, but statistically significant, increase in H3P-positive cells suggestive of
M-phase arrest (Figs. 2A–D and 2E) (p < 0.05, oneway ANOVA). Unlike with vincristine, H3P staining in
bortezomib-treated larvae was not evenly dispersed
throughout the embryo but was concentrated in the
dorsal aorta, caudal vein, or both, suggesting that
vascular or hematopoietic cells may be disproportionately affected. The magnitude of arrest was much
less than that for vincristine, but due to the fact that
H3P-positive cells were so densely packed in larvae
treated with 50 μM bortezomib, the extent of cell cycle
arrest was likely underestimated due to limitations in
the method of quantitation. No increase in mortality was observed with bortezomib, although some
morphological defects, such as dorsal tail curvature

Image capture and image analysis
Image stacks were obtained using a Zeiss
AxioImager epifluorescent compound microscope with
ApoTome (AT and F59) or a Nikon C1 laser scanning
confocal microscope (H3P and znp-1) equipped with
×20 air (N.A. 1.4), ×40 oil (N.A. 1.3), or ×60 water (N.A.
2.0) objectives. For quantitation of H3P-positive cells,
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Figure 1. Vincristine effects on cell cycle progression. (A–D) Lateral views of the trunk at 48 hours post-fertilization (hpf).
Area shown in (A–D) is represented by boxed area in (A ). (A) Control staining for histone H3 phosphate (H3P), an indicator
of M-phase arrest. (B–D) Vincristine causes a dose-dependent increase in the number of H3P-positive cells (p < 0.0001,
one-way ANOVA). (A –D ) Images of live 48 hpf larvae. (A ) Control larva. (B and C ) Morphology is normal in larvae treated with
25–50 μM vincristine. (D ) One hundred micromolar vincristine causes some ventral curvature of the axis. p Values: pair-wise
Student’s t -tests with Bonferroni correction. Scale bars = 200 μm.

and slight developmental delays, were observed at 25
and 50 μM (Figs. 2A –D ).

dose, suggesting that vincristine impairs trigeminal
and Rohon-Beard neurons similarly.
Bortezomib also impaired responses to touch in a
dose-dependent manner. At 50 μM, the highest dose
tested, only 3 of 10 larvae responded to all five stimuli
to the head, and only 5 of 10 responded to all five stimuli to the tail (Table 1). The effect on response to head
stimulation was statistically significant at 50 μM. While
its effect on the responses to head stimulus was statistically significant at 50 μM (p = 0.01, Fisher’s exact
test) and its effect on responses to tail stimulus was
not, the difference between the two effects was not
sufficient to suggest that bortezomib affects trigeminal
neurons any differently than Rohon-Beard neurons.

Vincristine and bortezomib reduce touch
responsiveness
Because the primary dose-limiting side effect of
both vincristine and bortezomib is sensory neuropathy,
we tested their effects on touch responsiveness.
The touch response in larval zebrafish relies upon
stimulation of either the trigeminal sensory neurons
in the head or Rohon-Beard cells in the trunk and
tail (Clarke et al., 1984; Sagasti et al., 2005). To
test whether these drugs might differentially affect
trigeminal and Rohon-Beard sensory neurons, larvae
were scored for responses to stimuli to either head or
tail. Vincristine caused a dose-dependent decrease in
the number of larvae that responded to stimuli to both
head and tail (Table 1). The effect of vincristine was
statistically significant for both head and tail stimuli
(p = 0.016 and 0.005, respectively, Fisher’s exact
test) at 100 μM. There was no significant difference
between responses to head and tail stimuli at any

Vincristine and bortezomib disrupt escape
swimming behavior
Because vincristine and bortezomib are also
known to cause motor neuropathy in mammalian
systems, we examined the effects of vincristine or
bortezomib on swimming behavior associated with
the escape response. Larval escape response is
79
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Figure 2. Bortezomib effects on cell cycle progression. (A–D) Lateral views of the trunk at 48 hours post-fertilization (hpf).
Areas shown represented by boxed area in (A ). (A) Control H3P staining. (B–D) Bortezomib causes a dose-dependent increase
in the number of H3P-positive cells (p < 0.05, one-way ANOVA). The H3P-positive cells appear to be concentrated in the dorsal
aorta and/or caudal vein (brackets in (D)). (A –D ) Images of live 48 hpf larvae. (A ) Control larva. (B ) Morphology is completely
normal in larvae treated with 10 μM bortezomib. (C ) Twenty-five micromolar bortezomib-treated larvae occasionally show
subtle defects, including dorsal curvature of the axis. (D ) Fifty micromolar bortezomib causes some curvature of the axis in
all larvae. These larvae also appear to be developmentally delayed. Scale bars = 200 μm.
Table 1. Summary of touch responses in drug-treated zebrafish larvae at 48 hpf.
Number with 100% response∗
Drug
Vincristine (μM)
0
50
100
Bortezomib (μM)
0
25
50

Mean number of responses ± SEM†

Head

Tail

Head

Tail

10/10
8/10
5/10 (p = 0.016)‡

10/10
7/10
4/10 (p = 0.005)‡

5.0 ± 0.00
4.6 ± 0.31
3.9 ± 0.41 (p = 0.03)§

5.0 ± 0.00
4.5 ± 0.31
4.2 ± 0.25 (p = 0.01)§

9/10
7/10
3/10 (p = 0.01)‡

9/10
5/10
5/10 (N.S.)‡

4.9 ± 0.10
4.7 ± 0.13
3.8 ± 0.33 (p = 0.01)§

4.9 ± 0.10
3.4 ± 0.64
3.6 ± 0.54 (N.S)§

hpf, hours post-fertilization; N.S., not statistically significant; SEM, standard error of the mean.
∗
Ten larvae for each condition were stimulated five times on the head and five times on the tail, and the presence or absence of a response
was recorded.
†Five is the maximum possible.
‡Fisher’s exact test.
§Mann-Whitney U -test.

often initiated in response to sensory input; however,
sensation is not a prerequisite for escape swimming
(Granato et al., 1996; Ribera and Nusslein-Volhard,
1998), so any changes observed may be attributable

to effects on motor circuitry. At 2 dpf, control
larvae exhibited classic escape responses, consisting
of one or two rapid, large-amplitude body bends
(‘‘C-bends’’) away from the stimulus, a counter bend
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Figure 3. Vincristine and bortezomib effects on escape swimming behavior. Select frames from movies taken at 500 fps.
Times in milliseconds. (A) Normal larva exhibits one strong C-bend (20 ms) followed by smaller amplitude curls, which propel
it away from the site of stimulation. Note that frames 120, 140, 160, and 180 represent successive curls to the same side,
indicating that the period of coiling is approximately 20 ms. (B) Fifty micromolar vincristine-treated larva exhibits a single
C-bend (20 ms) followed by a pause and then uncoordinated coiling that fails to propel the larva away from the site of stimulus.
(C) Twenty-five micromolar bortezomib-treated larva exhibits continuous high-angle C-bend-like contractions that fail to propel
it away from the site of stimulus.

for reorientation, then lower-amplitude undulations
that propel the larva away from the stimulus (Figs. 3A
and 4A; Movie S1). Larvae treated with 50 μM
vincristine usually exhibited a typical C-bend; however,
these were followed by irregular, lower-amplitude
body bends that generally failed to propel larvae
away from the stimulus (Figs. 3B and 4B; Movie S2).
Larvae treated with 100 μM vincristine also typically
performed C-bends at the outset of their response, but
these were followed by highly irregular, sometimes

unilateral, body bends. In addition, the frequency of
undulations was less than controls (Fig. 4C).
Bortezomib-treated larvae also demonstrated
abnormal escape responses. Larvae treated with
25 μM bortezomib responded to touch with repetitive,
high-amplitude C-bends. These high-amplitude bends
persisted until the termination of the response, rather
than transitioning to lower-amplitude undulations, and
they usually failed to propel the larvae away from
the stimulus (Figs. 3C and 4D; Movie S3). The mean
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Khan et al.

Journal of the Peripheral Nervous System 17:76–89 (2012)

Control

head-to-tail angle
(degrees)

A

0

B

50

100

150 200
time (msec)

250

C

350

D

Vincristine - 100 µM

Amplitude of
Contractions

head-to-tail angle
(degrees)

Max curl (degrees)

Vincristine - 50 µM

300

0

50

100

150

200

250

300

350

0

50

100

time (msec)

150

200

250

300

350

[Vincristine] (µM)

time (msec)

E

Bortezomib - 25 µM

Amplitude of
Contractions

F

Max curl (degrees)

head-to-tail angle
(degrees)

p = 0.007

0

50

100

150

200

250

300

350

[Bortezomib] (µM)

time (msec)

Figure 4. Kinematic analysis of escape behavior. Body bend angle, the angle of deviation of the tail from a neutral position, is
plotted for each treatment as a function of time. Different larvae are indicated by differently colored traces. (A) Normal larvae
typically exhibit one or two high-amplitude ‘‘C-bends,’’ characterized by a body bend angle of 150◦ or more. The initial C-bends
are followed by rapid, low-amplitude bends of approximately 55◦ . (B) Larvae treated with 50 μM vincristine typically exhibited
normal C-bends, followed by uncoordinated contractions, some of which were increased in amplitude relative to controls (e.g.,
orange trace) and others that were increased in duration (e.g., green trace) relative to controls. (C) Larvae treated with 100 μM
vincristine exhibited normal C-bends followed by uncoordinated contractions. In one case, the contractions were strictly
unilateral (green trace). (D) The mean tail curl amplitude of larvae treated with 100 μM vincristine was increased relative to
controls, but this difference was not significant (p = 0.15, Mann-Whitney U -test). (E) Larvae treated with 25 μM bortezomib
exhibited continuous high-amplitude C-bend-like contractions. (F) The contractions were significantly higher in amplitude than
propulsive body bends exhibited by control larvae (p = 0.007, Mann-Whitney U -test).

so abnormal as to preclude meaningful quantitative
analysis (data not shown).

body bend amplitude during the ‘‘swimming’’ phase
of the response was significantly greater than controls
(Fig. 4F; p = 0.007, Mann-Whitney U -test). While the
contraction amplitude was significantly increased, the
contraction velocity was decreased (compare slopes
of traces in Figs. 4A and 4E).
At 50 μM bortezomib, the highest dose tested,
larvae were generally unable to respond to stimulus.
The two larvae that exhibited any sort of response were

Vincristine and bortezomib reduce sensory
innervation density
Because vincristine- and bortezomib-treated larvae displayed reduced touch responses, we examined
sensory axon projections in larvae treated with either
drug. In this experiment, we observed significant
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Figure 5. Vincristine and bortezomib effects on sensory axon density. (A–H) Lateral views of 48 hours post-fertilization
larvae stained with anti-acetylated tubulin, which labels all axons. Only the sensory axons innervating the skin were imaged.
(A) Imaged area is indicated by box. (E) Control for both vincristine and bortezomib treatments. (I) Taken together, the
treatments caused a statistically significant alteration in sensory axon density (p < 0.0001 one-way ANOVA for all treatments).
At 100 μM, the effect of vincristine was statistically significant (p = 0.0059, Bonferroni post-hoc), as was the effect of
bortezomib at 50 μM (p = 0.0015, Bonferroni post-hoc). (J) Both vincristine and bortezomib showed apparent dose-dependent
effects on development of the lateral line. Scale bar = 50 μm.

reductions in the density of sensory axons in the skin
(p < 0.0001, one-way ANOVA for experiment). Individually, the effects of 100 μM vincristine (Figs. 5A–D and
5H) and 50 μM bortezomib (Figs. 5E–H and 5I) were
statistically significant (p = 0.0059 and 0.0015, respectively). Bortezomib seemed to have a greater effect on
fine processes than on large-diameter axons (Fig. 5H).
Both drugs also caused a dose-dependent reduction
and, in some cases, loss of the lateral line (Figs. 5D,
5H, and 5J).
As migration of the lateral line is frequently used
as a marker of larval development (Kimmel et al.,
1995), reduction/loss of the lateral line could indicate
a developmental delay. However, we observed little,
if any, concordance between reduction in the lateral
line and sensory innervation density, suggesting that
a developmental delay does not explain the observed
decrease in sensory innervation density.

It should be noted that the effects of both
drugs on sensory axons was quite variable, and the
morphologies observed for the highest dose of each
ranged from completely normal to severely disrupted
(Fig. S1).

Vincristine and bortezomib reduce motor axon
arbors
Because treated larvae also exhibited abnormal
escape behaviors, we analyzed motor axon morphology in treated larvae. For this analysis, we focused
on the arbors of caudal primary (CaP) neurons, which
extend ventrally and medially out of the spinal cord to
the ventral-most axial muscle, then turn laterally and
dorsally to innervate the exterior portion of the muscle. The main trunks of these primary motor axons
are established by 24 hpf but continue to grow and,
importantly, develop branches between 24 and 48 hpf
83

Khan et al.

Journal of the Peripheral Nervous System 17:76–89 (2012)

A

E

B

F

C

G

D

H

I

J

Figure 6. Vincristine and bortezomib effects on motor axon morphology. (A–H) High-magnification lateral views of 48 hours
post-fertilization larvae stained with znp-1, which labels motor neurons and their axons. The CaP motor axon extends ventrally
from the spinal cord and hooks around the ventral edge of the muscle to project dorsally and laterally to the outside of the
axial muscle. (A) Control motor axon staining for vincristine treatment. (B–D) Vincristine treatment significantly decreased
the surface area of motor axon arbors (p < 0.0001, one-way ANOVA). (I) This effect was individually significant at all doses
(p values indicated on graph). (E) Control staining for bortezomib treatment. (F–H) Bortezomib significantly decreased motor
axon arbor area (p = 0.0006, one-way ANOVA). (J) This effect was individually significant only at 50 μM (p value indicated on
graph). Interestingly, bortezomib appeared to decrease the area of branches, while the main axon trunk remained intact (e.g.,
arrowhead in (H)). p Values: pair-wise Student’s t -tests with Bonferroni correction. Scale bar = 50 μm.

(Myers, 1985; Myers et al., 1986). Vincristine caused
a statistically significant, dose-dependent reduction
in the areas of motor axon arbors (p < 0.0001, oneway ANOVA) (Figs. 6A–D and 6I). Vincristine appeared
to alter the integrity of both the main trunk of the
axon and branches but did not have any effect on the
distance traveled by the leading edge of the axon, suggesting that the effect of vincristine was primarily on
axons, not due to a developmental delay. This finding
suggests that vincristine may affect axon outgrowth,
maintenance, or both.
Bortezomib also caused a statistically significant,
dose-dependent decrease in the areas of motor
axon arbors (p = 0.0006, ANOVA) (Figs. 6E–H and 6J).
Interestingly, bortezomib seemed to affect branches

to a greater extent than the primary axon trunk, similar
to its effect on sensory axons (Fig. 6H).

Effects of vincristine and bortezomib on muscle
morphology
Because defects in muscle structure and function
could generate some of the neural and behavioral
abnormalities caused by vincristine or bortezomib,
we also examined axial muscle morphology in larvae treated with the intermediate and highest doses
of each drug. At intermediate doses (50 μM vincristine
and 25 μM bortezomib), the axial muscles appear normal (Figs. 7A, 7B, 7D, and 7E). At the highest dose
of each drug (100 μM vincristine and 50 μM bortezomib), however, individual fibers begin to separate
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Vincristine
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F
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25 µM

Figure 7. Vincristine and bortezomib effects on muscle morphology. Lateral views of 48 hours post-fertilization larvae stained
for F59, slow muscle myosin. (A) Muscle morphology in control larva for vincristine treatment. (B) Muscle morphology appears
normal at 50 μM vincristine. (C) Muscle begins to look disorganized at 100 μM vincristine. (D) Control larva for bortezomib
treatment. (B) Muscle morphology appears normal at 25 μM bortezomib. (C) Muscle begins to look disorganized at 50 μM
bortezomib. Black spots in (C) and (F) are pigment-containing melanophores in the overlying skin.

from one another, resulting in subtle disorganization of
the myotome (Fig. 7C and 7F).

the variability in our sensory axon data suggests that
this particular assay may not lend itself to large-scale
screens, any of the other assays employed here could
certainly be used.
Not surprisingly, both vincristine and bortezomib
impaired touch responses in zebrafish, consistent
with the side effects of these drugs in humans,
which frequently includes sensory defects (Bradley
et al., 1970; Richardson et al., 2003). The reduction in
sensory innervation that we observed was similar in
magnitude and may account for the reduced touch
responses. What is perhaps surprising is that the
sensory effects of these drugs were not even greater
given the fact that sensory impairment in humans is
the most common side effect of these drugs. This
difference may be due to differences between the
physiology of zebrafish and humans or it may simply
reflect differences between our assay systems.
Although their effects on the touch response were
similar, the effects of vincristine and bortezomib on
escape swimming differed in that vincristine resulted
in uncoordinated swimming, while bortezomib caused
an increase in the amplitude of contractions. The
discoordination caused by vincristine is consistent
with broad disruption of neural pathways that
coordinate this behavior. It is interesting to note that
although these larvae are uncoordinated, the left–right
alternating pattern of muscle contractions remains
largely intact, suggesting that defects in pathways that
govern reciprocal inhibition (Saint-Amant and Drapeau,
1998; Drapeau et al., 2002; Brustein et al., 2003; Buss
et al., 2003) do not primarily underlie the lack of
coordination.

Discussion
The primary dose-limiting side effect of several
important chemotherapeutic compounds, including
vincristine and bortezomib, is peripheral neuropathy.
A high priority has therefore been placed on developing
ways to minimize the neuropathic side effects while
retaining the therapeutic properties of these drugs
(Rosenthal and Kaufman, 1974; Cavaletti and NobileOrazio, 2007). To achieve this goal, it is essential to
establish model systems that can be used to help
elucidate the mechanisms by which these compounds
exert their effects in vivo. The zebrafish system has
been shown to be a useful model for a number of
neurological disorders (Oprea et al., 2008; Boon et al.,
2009; Kabashi et al., 2011), and vincristine has recently
been shown to be effective in a zebrafish model of
acute lymphoblastic leukemia (Mizgirev and Revskoy,
2010). The work described here demonstrates that
zebrafish can be used to study the neurotoxic effects
of chemotherapy drugs. Although we focus on late
embryonic/early larval development, the cell biological
mechanisms by which these compounds disrupt axon
outgrowth and cause peripheral neuropathy may be
similar. Indeed, vincristine has been demonstrated to
disrupt both assembly and stability of microtubules
(Himes et al., 1976), and our research has shown
that it affects both nascent and established zebrafish
axons equally (N.Benaich. unpublished data). Although
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By contrast, the repetitive, high-amplitude body
bends caused by bortezomib appear to result from a
failure of muscle contraction to propagate smoothly
down the body axis; rather, all of the muscles along
one side of the body appear to contract simultaneously,
although the left–right alternation of the contractions
appears again unaffected. This unusual behavior could
be caused by any number of mechanisms, but it is
worth noting that it is similar to that observed for
the techno trousers mutant, a loss-of-function mutant
in the glial glutamate transporter slc1a2b/EAAT2
(K. A. McKeown and G. B. Downes, unpublished data).
Differences in behaviors caused by the two
drugs are undoubtedly related to differences in
their biochemical mechanisms. Vincristine disrupts
microtubules, so it is therefore not surprising that
it causes defects in sensory and motor (and possibly
other) axons and subsequent discoordination of the
escape response. Because inhibiting the proteasome
likely alters many cellular pathways, the mechanisms
by which bortezomib affects axons is less clear. One
of the mechanisms by which it suppresses cancer
progression is through enhanced inhibition of the antiapoptotic transcription factor NF-κB (Hideshima et al.,
2002). However, the specific mechanisms underlying
its anti-proliferative and neurotoxic effects are not
well understood (Argyriou et al., 2008). Recent studies
have shown how the proteome of cancer cell lines is
altered by bortezomib (Chauhan et al., 2008; LoefflerRagg et al., 2009); a complementary approach could
be useful to discover how the neuronal proteome is
altered in order to better understand the mechanisms
of bortezomib-induced peripheral neuropathy. On the
other hand, although bortezomib is reportedly quite
specific for the proteasome (Lightcap et al., 2000),
recent in vitro studies and patient trials have shown
that the novel proteasome inhibitor carfilzomib does
not cause neurotoxicity (Arastu-Kapur et al., 2011;
Khan and Stewart, 2011), suggesting that bortezomib’s
neurotoxic side effects may be independent of its
effects on the proteasome. It remains to be seen
whether carfilzomib or other proteasome inhibitors act
similarly in the zebrafish system.
It is conceivable that the effects of vincristine
or bortezomib on behavior are due to generalized
toxicity to the embryo. However, the ranges of
vincristine (25–100 μM) and bortezomib (10–50 μM)
used here were not substantially different from the
range of concentrations (10–33 μM) typically used for
large-scale small-molecule screens in the zebrafish
(Kaufman et al., 2009; Rihel et al., 2010), and they
are at least an order of magnitude lower than the
concentrations of known compounds used in a recent
screen for cell cycle inhibitors (Murphey et al., 2006).
Furthermore, generalized toxicity would be expected

to result in impaired growth of the embryo; yet nearly
all treated embryos were normal in size except at the
highest dose of each drug. This, coupled with our
observation that treated larvae appear morphologically
indistinguishable from controls at doses at which
behavioral and cellular phenotypes are observed, again
suggests against general toxicity as a mechanism for
the observed defects.
Alternatively, the axon defects we observed could
be indirectly due to effects on other tissues, independent of toxicity. For example, the axon degeneration
observed in hereditary peripheral neuropathies is commonly secondary to myelin defects (Berger et al.,
2002). In addition, the defects in sensory (Paulus et al.,
2009) and/or motor (Lefebvre et al., 2004) axons seen
at the highest doses of each drug could be secondary
to the effects on muscle. (Conversely, the observed
muscle fiber disorganization could be a consequence of
failure of axons to properly innervate muscle.) We also
cannot rule out the possibility that the effects of the
drugs are due, at least in part, to changes in neuronal
physiology independent of the increase in excitability that results from increased sodium conductance.
These possibilities are all worth testing.
Many aspects of the mechanisms of cancer
development (Langenau and Zon, 2005; Yee and
Pack, 2005; Feitsma and Cuppen, 2008; Stoletov and
Klemke, 2008; Marques et al., 2009), cancer treatment
(Mizgirev and Revskoy, 2010), neuronal development
(Hutson and Chien, 2002), and neuromuscular disease
(Boon et al., 2009) are conserved between humans
and zebrafish. The results described here demonstrate
that two important chemotherapy drugs, vincristine
and bortezomib, cause neurodevelopmental defects in
zebrafish larvae. As the mechanisms underlying these
defects are likely to share features with peripheral
neuropathy in human patients, these results provide a
foundation for further analysis of the effects of these
and other drugs using zebrafish as a model system.
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Supporting Information

Movie S3. Escape response of bortezomib-treated larva.
High-speed video recording of a typical larva treated
with 25 μM bortezomib. The larva responds to touch by
performing continuous C-bend-like contractions. Video recorded
at 500 frames per second (fps) and displayed at 30 fps, or
approximately ×17 slower than real time.
Figure S1. Variations in sensory axon density. Lateral views
illustrating the range of sensory axon phenotypes within each
treatment group. ‘‘High density’’ and ‘‘low density’’ refer to
samples within each treatment group with the highest and
lowest innervation density, respectively. ‘‘Reduced lateral line’’
shows an example within treatment group with reduced or
absent lateral line. Note that overall density of sensory axons
is often normal in larvae lacking the lateral line (E, H, K). VCR,
vincristine. Bort, bortezomib.

Additional Supporting Information may be found in the online
version of this article:
Movie S1. Normal zebrafish larval escape response. Highspeed video recording of a typical control larva at approximately
50 hours post-fertilization exhibiting escape response to touch.
Larva responds to touch with one or two high-amplitude
body bends (C-bends), followed by low-amplitude left–right
alternating contractions that propel the larva away from the
site of stimulus. Video recorded at 500 frames per second (fps)
and displayed at 30 fps, or approximately ×17 slower than real
time.
Movie S2. Escape response of vincristine-treated larva. Highspeed video recording of a typical larva treated with
50 μM vincristine. Larva responds to touch with an initial
C-bend, but this is followed by irregular, uncoordinated
contractions. Video recorded at 500 frames per second (fps)
and displayed at 30 fps, or approximately ×17 slower than real
time.

Please note: Wiley-Blackwell are not responsible for the content
or functionality of any supporting materials supplied by the
authors. Any queries (other than missing material) should be
directed to the corresponding author for the article.
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